Carbamic acid,N-[2-[[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl]-3-methylphenyl]-,methyl ester Chemical Properties

Density 

1.21±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Soluble in DMSO

form 

Solid

pka

13.67±0.70(Predicted)

color 

Light yellow to yellow

Carbamic acid,N-[2-[[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl]-3-methylphenyl]-,methyl ester Usage And Synthesis

Description

Pumaprazole has been abandoned in favor of a pharmacologically better follow up compound presently under development at Byk Gulden. The WHO decided to label the APAs by the stem syllable “-prazole” in order “to maintain the number of stems at a manageable level”, irrespective of the completely different (i.e., reversible vs. covalent) modes of drug – target interactions by APAs and PPIs (WHO decision communicated on Nov. 30, 1995). Unfortunately, this pharmacologically misleading but legally binding decision will confuse the rational use and differential perception of APAs vs. PPIs in the future and counteracts the effort for an unambiguous terminology in pharmacology. It should be noted that the terms APAs and PPIs have been coined specifically to make a clearly recognizable distinction between the two chemically and mechanistically different classes of drugs.

Uses

Pumaprazole is a reversible proton pump antagonist.

in vivo

References

[1] Kromer W, et al. Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles. Pharmacology. 2000 May;60(4):179-87. DOI:10.1159/000028367